Treatment of Vulvovaginal candidiasis through Homoeopathic Medicine Sepia 200

A Double Blinded Parallel Arm Randomised Placebo controlled Trial on Sepia Officinalis 200 CH in management of Vulvo vaginal Candidiasis - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/092247

Enrollment

Registered

2025-08-04

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N768- Other specified inflammation of vagina and vulva Health Condition 2: N768- Other specified inflammation of vagina and vulva

Interventions

Intervention1: Homoeopathic drug Sepia Officinalis 200: Sepia Officinalis 200 once in a week for 6 months duration through oral administration Control Intervention1: Placebo: Placebo once in a week fo

Eligibility

Inclusion criteria

Inclusion criteria: Non-Pregnant Adult Females 18 Years to 70 Years Of Age Female Patient With Symptoms Correspond To Sepia Officinalis Clinical Signs With One Or More Symptoms Of Vulvovaginal Candidiasis

Exclusion criteria

Exclusion criteria: IMPAIRED IMMUNITY CHEMOTHERAPY ORAL CORTICOSTEROIDS PSYCHATRIC PATIENT PREGNANT WOMEN UNDER OTHER MEDICATIONS OR CONCOMITANT THERAPIES

Design outcomes

Primary

Measure	Time frame
Number Of Participants With Clinical Outcome Response During The Therapeutic Intervention Visit Combined Per Participant And Microbiological ResponseTimepoint: 0 days Baseline Assessment 7 days Second Assessment 14 days Third Assessment	—

Secondary

Measure	Time frame
Microbiological outcome and response during the study periodTimepoint: 6 months	—

Countries

India

Contacts

Public ContactSibin R A

Sarada krishna Homoeopathic medical college

hodcr@skhmc.org9443558483

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026